Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-30
2011-08-30
Sznaidman, Marcos L (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S559000
Reexamination Certificate
active
08008282
ABSTRACT:
The present invention is directed to methods for the prevention or inhibition of angiogenesis. The method is accomplished by the administration of an effective amount of 15-epi-16-(para-fluoro)-phenoxy-lipoxin A4, LXA4, 15-epi-LXA4or 15-R/S-methyl, LXA4and pharmaceutically acceptable salts, esters, amides, carboxylic acids, or prodrugs thereof, to a subject in need thereof. As a consequence of the action of the therapeutic agent, angiogenesis is prevented or inhibited in the subject.
REFERENCES:
patent: 4560514 (1985-12-01), Samuelsson et al.
patent: 4576758 (1986-03-01), Morris
patent: 4780281 (1988-10-01), Marnett et al.
patent: 5049681 (1991-09-01), Sato
patent: 5079261 (1992-01-01), Serhan et al.
patent: 5322699 (1994-06-01), Wright et al.
patent: 5441951 (1995-08-01), Serhan
patent: 5648512 (1997-07-01), Serhan
patent: 5650435 (1997-07-01), Madara et al.
patent: 5750354 (1998-05-01), Simchowitz et al.
patent: 5837283 (1998-11-01), McDonald
patent: 6048897 (2000-04-01), Serhan
patent: 6100296 (2000-08-01), Madara et al.
patent: 6177468 (2001-01-01), Madara et al.
patent: 6316648 (2001-11-01), Serhan
patent: 6329425 (2001-12-01), Madara et al.
patent: 6387953 (2002-05-01), Serhan
patent: 6627658 (2003-09-01), Serhan et al.
patent: 6653493 (2003-11-01), Serhan et al.
patent: 2002/0168361 (2002-11-01), Kelly
patent: 2004/0053998 (2004-03-01), Serhan et al.
patent: 62-198677 (1987-09-01), None
patent: 63-88153 (1988-04-01), None
patent: 1-228994 (1989-09-01), None
patent: 3-227922 (1991-10-01), None
patent: WO 94/29262 (1994-12-01), None
patent: WO 95/01179 (1995-01-01), None
patent: WO 98/11049 (1998-03-01), None
patent: WO 00/54767 (2000-09-01), None
patent: WO 00/55109 (2000-09-01), None
patent: WO 01/70664 (2001-09-01), None
Ather et. al., Wound Management—Developmentts in treatment options, European Dermatology review, 2006, 59-60.
Kramer, Effect of zpovidone-iodine on wound healing: a review, Journal of vascular nursing, 1999, 27:17-21.
Krishnan, Current Anaesthesia and critical care (2006) 17:21-27.
Ganz T., et al., “Antimicrobial Peptides of Phagocytes and Epithelia”, Seminars in Hematology, Oct. 1997, vol. 34, No. 4, pp. 343-354, XP009009059.
Elsbach P. et al., “Role of the Bactericidal/Permeability-Increasing Protein in Host Defense”, Current Opinion in Immunology, Feb. 1998, vol. 10, No. 1, pp. 45-49, XP002238031.
Canny Geraldine et al., “Lipid Mediator-Induced Expression of Bactericidal/Permeability-Increasing Protein (BPI) in Human Mucosal Epithelia”, Proceedings of the National Academy of Sciences of the United States of America, Mar. 2002, vol. 99, No. 6, pp. 3902-3907, XP002238032.
Levy Ofer, “Therapeutic Potential of the Bactericidal/Permeability-Increasing Protein”, Expert Opinion of Investigational Drugs, Feb. 2002, vol. 11, No. 2, pp. 159-167, XP001147178.
Levy Ofer, “A Neutrophil-Derived Anti-Infective Molecule: Bactericidal/Permeabilty-Increasing Protein”, Antimicrobial Agents and Chemotherapy, United States Nov. 2000, pp. 2925-2931, XP002238033.
Levy Ofer, “Antimicrobial Proteins and Peptides of Blood: Templates for Novel Antimicrobial Agents”, Blood, Oct. 15, 2000, vol. 96, No. 8, pp. 2664-2672, XP002238034.
Takano, T. et al., Neutrophil-meidated Changes in Vascular Permeability are Inhibited by Topical Application of Aspirin-triggered 15-epi-lipoxin A4 and Novel Lipoxin B4 Stable Analogues:,J. Clin. Invest., vol. 101, No. 4, 1998, pp. 819-826.
Corey, E.J. et al., “On the Synthesis and Structure of Lipoxin B”,Tetrahedron Letters, vol. 26, No. 16, 1985, pp. 1919-1922.
Samuelsson, B., “An Elucidation of Arachidonic Acid Cascade Discovery of Prostaglandins, Thromboxane and Leukotrienes”,Drugs, vol. 33, Supp. 1, 1987, pp. 209.
Nash, S. et al.,“Effects of Polymorphonuclear Leukocyte Transmigration on the Barrier Function of Cultured Intestinal Epithelial Monolayers”,J. Clin. Invest., vol. 80, 1987, pp. 1104-1113.
Popov, G. K., et al., “Effect of Lipoxin B on Colony-Forming Ability of Human Peripheral Blood Mononuclears in a Diffusion Chamber”,Chelyabinsk Medical Institute, Department of Pathophysiology and Section of Human Cardiovascular Pathology. Translated from Byulleten‘ Eksperimental’ noi Biologii i Meditsiny, vol. 107, No. 1, 1989, pp. 80-83.
Nicolaou, K.C., et al., “Identification of a novel 7-cis-11-trans-lipoxin A4 generated by human neutrophils: total synthesis, spasmogenic activities and comparison with other geometric isomers of lipoxins A4 and B4”,Biochimica et Biophysica Acts, No. 1003, 1989, pp. 44-53.
Nicolaou, K.C. et al., “Total Synthesis of Novel Geometric Isomers of Lipoxin A4 and Lipoxin B4”,Reprinted from the Journal of Organic Chemistry, vol. 54, 1989, pp. 5527-5535.
Nigam, S., et al., “Lipoxin A4 and Lipoxin B4 Stimulate the Release but Not the Oxgenation of Arachidonic Acid in Human Neutrophils: Dissociation Between Lipid Remodeling and Adhesion”,Journal of Cellular Physiology, vol. 143, 1990, pp. 512-523.
Fiore, S., et al., “The Lipoxin Biosynthetic Circuit and Their Actions with Human Neutrophils”,Advances in Experimental Medicine and Biology, vol. 314, 1991, pp. 109-132.
Pettitt, T.R., et al. “Synthesis of Lipoxins and Other Lipoxygenase Products by Macrophages from the Rainbow Trout, Oncorhynchus mykiss”,The Journal of Biological Chemistry, vol. 266, No. 14, 1991, pp. 8720-8726.
Parkos, C.A., et al., “Neutrophil Migration across a Cultured Intestinal Epithelium”,J. Clin. Invest., vol. 88, 1991, pp. 1605-1612.
Lee, T.H., et al. “Inhibition of Leukotriene B4-Induced Neutrophil Migration by Lipoxin A4: Structure-Function Relationships”,Biochemical and Biophysical Research Communications, vol. 180, No. 3, 1991, pp. 1416-1421.
Serhan, C., “Lipoxins: Eicosanoids Carrying Intra- and Intercellular Messages”,Journal of Bioenergetics and Biomembranes, vol. 23, No. 1, 1991, pp. 105-122.
Brady, H.R., et al., “Leukotrienes stimulate neutrophil adhesion to mesangial cells: modulation with lipoxins”,American Journal Physiology, vol. 259, 1990, pp. F809-F815.
Nicolaou, K.C., et al., “Lipoxins and Related Eicosanoids: Biosynthesis, Biological Properties, and Chemical Synthesis”,Angew, Chem. Int. Ed. Engl., vol. 30, 1991, pp. 1100-1116.
Badr, K.F., “15-Lipoxygenase products as leukotriene antagonists: Therapeutic potential in glomerulonephritis”,Kidney International, vol. 42, Supp. 38, 1991, pp. S101-S108.
Fiore, S., et al., “Lipoxin Recognition Sites”,The Journal of Biological Chemistry, vol. 267, No. 23, 1992, pp. 16168-16176.
Parkos, C.A., et al., “Neutrophil Migration Across a Cultured Epithelial Monolayer Elicits a Biphasic Resistance Response Representing Sequential Effects on Transcellular and Paracellular Pathways”,The Journal of Cell Biology, vol. 117, No. 4, 1992, pp. 757-764.
Madara, J.L., et al., “A Simple Approach to Measurement of Electrical Parameters of Cultured Epithelia Monolayers: Use in Assessing Neutrophil-Epithelial Interactions”,J. Tiss. Cult. Meth., vol. 14, 1992, pp. 209-216.
Kathoh, T., et al., “Renal hemodynamic actions of lipoxins in rats: a comparative physiological study”,American Journal Physiology, vol. 263, 1992, pp. F436-F442.
Folkman, J., et al., “Angiogensis”,J. Biol. Chem., 267, 1992, pp. 10931-10934.
Lederman, S. et al., “Identification of a Novel Surface Protein on Activated CD4+ T Cells That Induces Contact-dependent B Cell Differentiation (Help)”,J. Exp. Med., vol. 175, 1992, pp. 1091-1101.
Hla, T.A., et al. “Cyclooxygenase Gene Expression in Inflammation and Angiogensis”.Annals N.Y. Acad. Sci., vol. 696, 1993, pp. 197-204.
Madara, J.L., et al. “5′-Adenosine Monophosphate is the Neutrophil-dervied Paracrine Factor that Elicits Chloride Secretion from T84 Intestinal Epithelial Cell Monola
Fierro Iolanda M.
Serhan Charles N.
Fairman Colin L.
Fulbright & Jaworski
Rothenberger Scott D.
Sznaidman Marcos L
The Brigham & Women's Hospital, Inc.
LandOfFree
Lipoxin analogs as novel inhibitors of angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lipoxin analogs as novel inhibitors of angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipoxin analogs as novel inhibitors of angiogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2750926